Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
TargTex
TargTex is a drug development company focused on creating localized therapies for hard-to-treat tumors, particularly Glioblastoma. Their lead product is a perioperative hydrogel that delivers a drug…
TargTex
TargTex is a drug development company focused on creating localized therapies for hard-to-treat tumors, particularly Glioblastoma. Their lead product is a perioperative hydrogel that delivers a drug…
TL;DR
Headquarters: Torres Vedras / Lisbon, Portugal
Founded: 2019
Focus: Localized, adjunct-to-surgery therapies for hard-to-treat solid tumors (lead program: glioblastoma hydrogel)
Lead product / designation: Perioperative hydrogel; orphan drug designation (TTX101)
Notable funders: European Innovation Council (EIC), Portugal Ventures
Company Overview
Problem Domain
Oncology — hard-to-treat solid tumors, notably glioblastoma
Founded
2019
Industry
Biotechnology
Funding Track Record
€2.5M
EIC award (grant) listed for June 2023
€2M
Seed-extension financing round with €2M invested including pharmaceutical partner Basi and Portugal Ventures
Investor Signal
“Received competitive public grant funding (EIC) and backing from institutional investor Portugal Ventures”